WO2010002862A3 - Protéines se liant au récepteur 3 du facteur de croissance des fibroblastes (fgfr3) - Google Patents

Protéines se liant au récepteur 3 du facteur de croissance des fibroblastes (fgfr3) Download PDF

Info

Publication number
WO2010002862A3
WO2010002862A3 PCT/US2009/049211 US2009049211W WO2010002862A3 WO 2010002862 A3 WO2010002862 A3 WO 2010002862A3 US 2009049211 W US2009049211 W US 2009049211W WO 2010002862 A3 WO2010002862 A3 WO 2010002862A3
Authority
WO
WIPO (PCT)
Prior art keywords
fgfr3
growth factor
factor receptor
fibroblast growth
binding proteins
Prior art date
Application number
PCT/US2009/049211
Other languages
English (en)
Other versions
WO2010002862A2 (fr
Inventor
Zhigang Weng
William M. Winston, Jr.
Lyne Breault
Kristan Meetze
Solly Weiler
Jeno Gyuris
Original Assignee
Aveo Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals, Inc. filed Critical Aveo Pharmaceuticals, Inc.
Priority to EP09774313A priority Critical patent/EP2313435A4/fr
Publication of WO2010002862A2 publication Critical patent/WO2010002862A2/fr
Publication of WO2010002862A3 publication Critical patent/WO2010002862A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des anticorps monoclonaux qui se lient au récepteur 3 du facteur de croissance des fibroblastes (FGFR3) et inhibent l'activation de celui-ci. Ces anticorps peuvent servir à traiter des maladies et des troubles de la prolifération cellulaire, y compris certaines formes de cancer, qui sont associés à l'activation of FGFR3.
PCT/US2009/049211 2008-07-01 2009-06-30 Protéines se liant au récepteur 3 du facteur de croissance des fibroblastes (fgfr3) WO2010002862A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09774313A EP2313435A4 (fr) 2008-07-01 2009-06-30 Protéines se liant au récepteur 3 du facteur de croissance des fibroblastes (fgfr3)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7727808P 2008-07-01 2008-07-01
US61/077,278 2008-07-01

Publications (2)

Publication Number Publication Date
WO2010002862A2 WO2010002862A2 (fr) 2010-01-07
WO2010002862A3 true WO2010002862A3 (fr) 2010-05-27

Family

ID=41464552

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/049211 WO2010002862A2 (fr) 2008-07-01 2009-06-30 Protéines se liant au récepteur 3 du facteur de croissance des fibroblastes (fgfr3)

Country Status (3)

Country Link
US (1) US8187601B2 (fr)
EP (1) EP2313435A4 (fr)
WO (1) WO2010002862A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410250B2 (en) 2009-03-25 2013-04-02 Genentech, Inc. Anti-FGFR3 antibodies and methods using same

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1423428B2 (fr) 2001-06-20 2012-11-14 Fibron Ltd. Anticorps bloquant l'activation de fgfr3, procedes de criblage et utilisations associes
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
EP1797084A1 (fr) * 2004-09-20 2007-06-20 4Sc Ag NOUVEAUX INHIBITEURS HÉTÉROCYCLIQUES DU NF-kB
PL2173379T3 (pl) 2007-07-02 2016-02-29 Oncomed Pharm Inc Kompozycje oraz sposoby leczenia i diagnozowania nowotworu
AR073770A1 (es) * 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
CN107253992B (zh) 2010-05-27 2022-03-11 根马布股份公司 针对her2的单克隆抗体
CA2832389A1 (fr) 2011-04-20 2012-10-26 Genmab A/S Anticorps bispecifiques contre her2 et cd3
CA2832387A1 (fr) * 2011-04-20 2012-10-26 Genmab A/S Anticorps bispecifiques contre her2
EP2710042A2 (fr) 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Protéines de fusion contenant un fab multi-spécifique et procédé d'utilisation
WO2013012747A1 (fr) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Agents de fixation aux protéines rspo et leurs utilisations
JP2015527869A (ja) 2011-08-26 2015-09-24 メリマック ファーマシューティカルズ インコーポレーティッド タンデムＦｃ二重特異性抗体
IN2014CN03555A (fr) 2011-10-25 2015-07-03 Onclave Therapeutics Ltd
SG11201401518TA (en) 2011-10-28 2014-05-29 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
WO2013088191A1 (fr) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagoniste du récepteur 3 du facteur de croissance des fibroblastes (fgfr3) à utiliser dans le traitement ou la prévention de troubles squelettiques liés à une activation anormale du fgfr3
WO2014012007A2 (fr) 2012-07-13 2014-01-16 Oncomed Pharmaceuticals, Inc. Agents de liaison des protéines rspo3 et leurs utilisations
CN104662044B (zh) 2012-08-24 2018-10-30 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
MX369550B (es) * 2012-09-27 2019-11-12 Chugai Pharmaceutical Co Ltd Gen de fusion del receptor de factor de crecimiento de fibroblastos 3 (fgfr3) y medicamentos farmaceutico para tratar el mismo.
KR20160002681A (ko) 2013-01-16 2016-01-08 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드
WO2014138449A1 (fr) 2013-03-06 2014-09-12 Merrimack Pharmaceuticals, Inc. Anticorps bispécifiques anti-c-met à fc en tandem
KR20150123250A (ko) 2013-03-06 2015-11-03 제넨테크, 인크. 암 약물 내성의 치료 및 예방 방법
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
PT2992013T (pt) 2013-04-29 2020-03-05 Teva Pharmaceuticals Australia Pty Ltd Anticorpos anti-cd38 e fusões a interferão alfa-2b atenuado
US10780182B2 (en) 2014-04-25 2020-09-22 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
DK3142750T3 (da) 2014-05-13 2020-09-14 Univ Pennsylvania Sammensætninger omfattende aav, som udtrykker dobbelt-antistofkonstrukter og anvendelser deraf
US20230190750A1 (en) 2014-06-13 2023-06-22 Genentech, Inc. Methods of treating and preventing cancer drug resistance
EP3180027A4 (fr) * 2014-08-15 2018-01-10 Oncomed Pharmaceuticals, Inc. Agents de liaison de rspo1 et leurs utilisations
EP3193935A4 (fr) 2014-09-16 2018-03-21 Oncomed Pharmaceuticals, Inc. Traitement de maladies fibrotiques
CA2965414C (fr) 2014-10-29 2024-01-09 Teva Pharmaceuticals Australia Pty Ltd Variantes de l'interferon .alpha.2.beta.
CA2961439A1 (fr) 2014-11-05 2016-05-12 Genentech, Inc. Anticorps anti-fgfr2/3 et procedes d'utilisation de ceux-ci
US20180237424A1 (en) 2015-03-03 2018-08-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Fgfr3 antagonists
US10870701B2 (en) 2016-03-15 2020-12-22 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
CN109069602B (zh) * 2016-04-14 2022-11-22 刘扶东 抑制scube2，一种新颖vegfr2辅助受体，抑制肿瘤血管发生
IL299099A (en) 2016-06-27 2023-02-01 Univ California Combinations of cancer treatments
MX2018016257A (es) 2016-07-07 2019-11-21 Therachon Sas Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos.
US10722589B2 (en) 2017-04-03 2020-07-28 Covagen Ag FGFR3 binding molecules
US11359014B2 (en) 2017-05-16 2022-06-14 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
US20210024936A1 (en) * 2018-04-09 2021-01-28 Board Of Regents, The University Of Texas System Therapeutic targeting of oncogenes using exosomes
EA202190183A1 (ru) * 2018-07-27 2021-05-18 Алектор Ллс Антитела к siglec-5 и способы их применения
CN116323666A (zh) 2020-08-21 2023-06-23 建新公司 Fgfr3抗体和使用方法
CN114716548A (zh) * 2021-01-05 2022-07-08 (株)爱恩德生物 抗-fgfr3抗体及其用途
WO2023113806A1 (fr) 2021-12-16 2023-06-22 Affinia Therapeutics, Inc. Vaa recombinant pour le traitement d'une maladie neurale
EP4323531A1 (fr) 2021-04-12 2024-02-21 Affinia Therapeutics Inc. Aav recombinant pour le traitement d'une maladie neurale
EP4329885A1 (fr) 2021-04-27 2024-03-06 Generation Bio Co. Vecteurs d'adn non viraux exprimant des anticorps thérapeutiques et leurs utilisations
WO2023177655A1 (fr) 2022-03-14 2023-09-21 Generation Bio Co. Compositions vaccinales prime-boost hétérologues et méthodes d'utilisation
US20240158515A1 (en) * 2022-11-14 2024-05-16 Regeneron Pharmaceuticals, Inc. Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereof
US20240247069A1 (en) 2023-01-13 2024-07-25 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010029293A1 (en) * 1992-01-27 2001-10-11 Icos Corporation Icam-related protein
US20020098189A1 (en) * 2000-03-01 2002-07-25 Young James F. High potency recombinant antibodies and method for producing them
US20030077793A1 (en) * 1996-06-25 2003-04-24 The Trustees Of Columbia University In The City Of New York Anti-cocaine catalytic antibody
US20030152571A1 (en) * 1997-03-12 2003-08-14 Smithkline Beecham Corporation Anti-alphabeta3 humanized monoclonal antibodies
US20030211106A1 (en) * 2000-08-21 2003-11-13 Tornetta Mark A Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
US20040005643A1 (en) * 2002-02-26 2004-01-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Anti-human tenascin monoclonal antibody
US20040034888A1 (en) * 1999-05-06 2004-02-19 Jingdong Liu Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US20040038339A1 (en) * 2000-03-24 2004-02-26 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
US20040044187A1 (en) * 1998-04-03 2004-03-04 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
US20040052783A1 (en) * 1992-03-27 2004-03-18 Protein Design Labs, Inc. Humanized antibodies against CD3
JP2004121026A (ja) * 2002-09-30 2004-04-22 Univ Nihon グリコシルトランスフェラーゼに対する抗体分子の遺伝子工学的製造法
US20050208042A1 (en) * 1999-02-12 2005-09-22 Genetics Institute, Inc. Humanized immunoglobulin reactive with B7 molecules and methods of treatment therewith
US20060030015A1 (en) * 2002-07-19 2006-02-09 Towa Kagaku Co., Ltd. Novel process for producing antibody enzyme, novel antibody enzyme and utilization thereof
US20060263369A1 (en) * 2002-11-20 2006-11-23 Roy Bicknell Antibodies, polypeptides and uses thereof
US20070025992A1 (en) * 2003-07-18 2007-02-01 Mochida Pharmaceutical Co., Ltd Monoclonal antibody against platelet membrane glycoprotein VI
US20070059306A1 (en) * 2005-07-25 2007-03-15 Trubion Pharmaceuticals, Inc. B-cell reduction using CD37-specific and CD20-specific binding molecules
US20070178095A1 (en) * 2004-03-23 2007-08-02 Eli Lilly And Company Anti-myostatin antibodies
US20070248605A1 (en) * 2003-12-19 2007-10-25 Five Prime Therapetutics, Inc. Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
US7288637B2 (en) * 2000-03-16 2007-10-30 Ramot At Tel Aviv University Ltd. Single chain antibody against mutant p53
US7319139B2 (en) * 2001-01-29 2008-01-15 Biogen Idec, Inc. TAG-72 specific CH2 domain deleted antibodies
US20080038257A1 (en) * 2006-06-02 2008-02-14 May Han Hepatocyte growth factor (hgf) binding proteins
WO2008020586A1 (fr) * 2006-08-14 2008-02-21 Forerunner Pharma Research Co., Ltd. diagnostic et traitement du cancer à l'aide de l'anticorps anti-desmogléine-3
WO2008062063A1 (fr) * 2006-11-24 2008-05-29 Pierre Fabre Medicament Nouveaux anticorps anti-prolifération

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0481000T3 (da) 1989-07-06 1999-11-15 Univ California Receptorer for fibroblastvækstfaktorer
AU6446194A (en) 1993-03-17 1994-10-11 Whittier Institute For Diabetes And Endocrinology, The Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US20030206912A1 (en) 1998-06-12 2003-11-06 Yeda Research And Development Co., Ltd. FGFR3 as a marker for mesenchymal skeletal progenitor cells
EP1208231B2 (fr) 1999-05-05 2009-12-30 Institut Curie Moyens de detection et de traitement des pathologies associees au fgfr3
AU1410801A (en) 1999-11-17 2001-05-30 Compugen Ltd. Variants of alternative splicing
US20040043930A1 (en) 2000-02-08 2004-03-04 Anderson David W. Novel proteins and nucleic acids encoding same
US20020111302A1 (en) 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
WO2002087618A1 (fr) 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Methode de prevention et de traitement du cancer
EP1423428B2 (fr) 2001-06-20 2012-11-14 Fibron Ltd. Anticorps bloquant l'activation de fgfr3, procedes de criblage et utilisations associes
CA2459219A1 (fr) 2001-09-17 2003-03-27 Protein Design Labs, Inc. Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer
US20060194265A1 (en) 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
US20070237770A1 (en) 2001-11-30 2007-10-11 Albert Lai Novel compositions and methods in cancer
ES2363765T3 (es) 2002-01-31 2011-08-16 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Agonistas de fgfr.
WO2003083046A2 (fr) 2002-03-08 2003-10-09 Curagen Corporation Nouvelles proteines et acides nucleiques codant pour de telles proteines
WO2004022095A1 (fr) 2002-09-04 2004-03-18 Abtech Anticorps anti-idiotypiques utiles en tant qu'agonistes d'un recepteur vegf ou fgf pour la therapie osseuse
US20040253606A1 (en) 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
AU2003287918A1 (en) 2002-12-20 2004-07-14 Enkam Pharmaceuticals A/S Method of modulation of interaction between receptor and ligand
WO2004074506A2 (fr) 2003-02-13 2004-09-02 Mergen Ltd Sequences polynucleotidiques et polypeptides codes correspondants de proteines specifiques secretees et liees a la membrane sur-exprimees dans certains cancers
ES2330634T3 (es) 2003-03-26 2009-12-14 Progenika Biopharma, S.A. Metodo in vitro para detectar carcinoma transicional de vejiga.
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
DE60319240D1 (de) 2003-12-19 2008-04-03 Charite Universitaetsmedizin Verwendung von Liganden von CD52 Antigen zur Behandlung von soliden Tumoren und von Knochenkrebserkrankungen
CA2558758C (fr) 2004-02-24 2015-06-23 Allergan, Inc. Dosage de criblage de toxines botulinique
WO2005115363A2 (fr) 2004-05-25 2005-12-08 Yale University Methode de traitement de troubles squelettiques resultant d'une anomalie du recepteur du facteur de croissance (fgfr)
US20090175866A1 (en) 2004-11-04 2009-07-09 Avner Yayon Treatment of b-cell malignancies
EP1659175A1 (fr) 2004-11-18 2006-05-24 Institut Curie Altérations des kératoses séborrhéiques et applications dérivées
JP2008535853A (ja) 2005-04-07 2008-09-04 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 癌関連遺伝子
US7498142B2 (en) 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
US8101721B2 (en) 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010029293A1 (en) * 1992-01-27 2001-10-11 Icos Corporation Icam-related protein
US20040052783A1 (en) * 1992-03-27 2004-03-18 Protein Design Labs, Inc. Humanized antibodies against CD3
US20030077793A1 (en) * 1996-06-25 2003-04-24 The Trustees Of Columbia University In The City Of New York Anti-cocaine catalytic antibody
US20030152571A1 (en) * 1997-03-12 2003-08-14 Smithkline Beecham Corporation Anti-alphabeta3 humanized monoclonal antibodies
US20040044187A1 (en) * 1998-04-03 2004-03-04 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
US20050208042A1 (en) * 1999-02-12 2005-09-22 Genetics Institute, Inc. Humanized immunoglobulin reactive with B7 molecules and methods of treatment therewith
US20040034888A1 (en) * 1999-05-06 2004-02-19 Jingdong Liu Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US20020098189A1 (en) * 2000-03-01 2002-07-25 Young James F. High potency recombinant antibodies and method for producing them
US7288637B2 (en) * 2000-03-16 2007-10-30 Ramot At Tel Aviv University Ltd. Single chain antibody against mutant p53
US20040038339A1 (en) * 2000-03-24 2004-02-26 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
US20030211106A1 (en) * 2000-08-21 2003-11-13 Tornetta Mark A Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
US7319139B2 (en) * 2001-01-29 2008-01-15 Biogen Idec, Inc. TAG-72 specific CH2 domain deleted antibodies
US20040005643A1 (en) * 2002-02-26 2004-01-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Anti-human tenascin monoclonal antibody
US20060030015A1 (en) * 2002-07-19 2006-02-09 Towa Kagaku Co., Ltd. Novel process for producing antibody enzyme, novel antibody enzyme and utilization thereof
JP2004121026A (ja) * 2002-09-30 2004-04-22 Univ Nihon グリコシルトランスフェラーゼに対する抗体分子の遺伝子工学的製造法
US20060263369A1 (en) * 2002-11-20 2006-11-23 Roy Bicknell Antibodies, polypeptides and uses thereof
US20070025992A1 (en) * 2003-07-18 2007-02-01 Mochida Pharmaceutical Co., Ltd Monoclonal antibody against platelet membrane glycoprotein VI
US20070248605A1 (en) * 2003-12-19 2007-10-25 Five Prime Therapetutics, Inc. Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
US20070178095A1 (en) * 2004-03-23 2007-08-02 Eli Lilly And Company Anti-myostatin antibodies
US20070059306A1 (en) * 2005-07-25 2007-03-15 Trubion Pharmaceuticals, Inc. B-cell reduction using CD37-specific and CD20-specific binding molecules
US20080038257A1 (en) * 2006-06-02 2008-02-14 May Han Hepatocyte growth factor (hgf) binding proteins
WO2008020586A1 (fr) * 2006-08-14 2008-02-21 Forerunner Pharma Research Co., Ltd. diagnostic et traitement du cancer à l'aide de l'anticorps anti-desmogléine-3
WO2008062063A1 (fr) * 2006-11-24 2008-05-29 Pierre Fabre Medicament Nouveaux anticorps anti-prolifération

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410250B2 (en) 2009-03-25 2013-04-02 Genentech, Inc. Anti-FGFR3 antibodies and methods using same
US8710189B2 (en) 2009-03-25 2014-04-29 Genentech, Inc. Anti-FGFR3 antibodies and methods using same

Also Published As

Publication number Publication date
US20100003258A1 (en) 2010-01-07
US8187601B2 (en) 2012-05-29
EP2313435A4 (fr) 2012-08-08
WO2010002862A2 (fr) 2010-01-07
EP2313435A2 (fr) 2011-04-27

Similar Documents

Publication Publication Date Title
WO2010002862A3 (fr) Protéines se liant au récepteur 3 du facteur de croissance des fibroblastes (fgfr3)
WO2011143318A3 (fr) Anticorps anti-fgfr2
WO2011136911A3 (fr) Anticorps anti-erbb3
WO2009140177A3 (fr) Anticorps anti-fn14 et leurs utilisation
WO2008140493A3 (fr) Anticorps de la famille anti-egfr, anticorps de la famille anti-egfr bispécifiques et leurs procédés d'utilisation
WO2008104183A3 (fr) Compositions d'anticorps recombinants dirigés contre le récepteur du facteur de croissance épidermique
WO2007144893A3 (fr) Anticorps bloquant l'activation du récepteur du facteur de croissance des fibroblastes et leurs procédés d'utilisation
NZ597694A (en) Anti-IGF antibodies
WO2008150485A3 (fr) Compositions thérapeutiques et procédés
WO2007143098A8 (fr) Protéines de liaison au facteur de croissance des cellules hépatiques (hgf)
WO2010096434A3 (fr) Protéines de liaison spécifique et leurs utilisations
NZ602220A (en) Antibodies with ph dependent antigen binding
EP3199551A3 (fr) Anticorps entièrement humains de btla
EA201290570A1 (ru) Конструкты, связывающиеся с ron, и способы их использования
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
NZ595641A (en) Humanized anti-egfl7 antibodies and methods using same
WO2010081679A3 (fr) Anticorps dirigés contre le récepteur humain de l'érythropoïétine
WO2007116360A3 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes
WO2009073533A3 (fr) Conjugués anticorps monoclonal-médicaments anti-b7h4 et procédés d'utilisation associés
WO2008155387A3 (fr) Anticorps anti-igf
WO2011041319A8 (fr) Protéines de liaison spécifiques et leurs utilisations
WO2008151819A3 (fr) Traitement de tumeurs à l'aide d'un anticorps anti-l1 spécifique
WO2009055074A8 (fr) Compositions et procédés thérapeutiques
WO2009048769A3 (fr) Anticorps monoclonaux spécifiques du virus de la vaccine h3l et b5r, procédés de préparation et d'utilisation correspondants
WO2011156617A3 (fr) Anticorps anti-egfr

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09774313

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009774313

Country of ref document: EP